CA2266619A1 - Administration non invasive de vecteur viraux aav - Google Patents

Administration non invasive de vecteur viraux aav Download PDF

Info

Publication number
CA2266619A1
CA2266619A1 CA002266619A CA2266619A CA2266619A1 CA 2266619 A1 CA2266619 A1 CA 2266619A1 CA 002266619 A CA002266619 A CA 002266619A CA 2266619 A CA2266619 A CA 2266619A CA 2266619 A1 CA2266619 A1 CA 2266619A1
Authority
CA
Canada
Prior art keywords
aav
gene
vector
interest
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002266619A
Other languages
English (en)
Inventor
Richard Snyder
James Mcarthur
Olivier Danos
Richard Mulligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2266619A1 publication Critical patent/CA2266619A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nouveaux procédés pour administrer des vecteurs recombinés de virus AAV pour produire une expression efficace, longue durée, d'un gène d'intérêt chez des animaux, y compris chez l'homme. L'invention concerne des méthodes d'injection sous-cutanée de vecteurs AAV recombinés contenant un gène particulier codant n'importe quel polypeptide, ribozyme, acid nucléique, ou oligonucléotide antisens diffusibles en vue d'une thérapie génique. Ces méthodes offrent des avantages significatifs, parmi lesquels la possibilité d'administrer n'importe quel polypeptide ou acide nucléique diffusible de dimension prédéterminée par injection sous-cutanée, pour obtenir une expression importante et longue durée, dans des régions proches ou distantes du site d'injection sous-cutanée.
CA002266619A 1996-09-25 1997-09-25 Administration non invasive de vecteur viraux aav Abandoned CA2266619A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2663896P 1996-09-25 1996-09-25
US60/026,638 1996-09-25
PCT/US1997/016929 WO1998013070A1 (fr) 1996-09-25 1997-09-25 Administration non invasive de vecteur viraux aav

Publications (1)

Publication Number Publication Date
CA2266619A1 true CA2266619A1 (fr) 1998-04-02

Family

ID=21832986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266619A Abandoned CA2266619A1 (fr) 1996-09-25 1997-09-25 Administration non invasive de vecteur viraux aav

Country Status (6)

Country Link
EP (1) EP0928202A4 (fr)
JP (1) JP2001501819A (fr)
KR (1) KR20000048623A (fr)
AU (1) AU743335B2 (fr)
CA (1) CA2266619A1 (fr)
WO (1) WO1998013070A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005376B1 (fr) * 1997-03-14 2010-11-03 The Children's Hospital of Philadelphia Compositions utilisees en therapie genique dans le traitement de l'hemophilie
EP1279740A1 (fr) * 2001-07-26 2003-01-29 Vrije Universiteit Brussel Vector recombinant dérivé d'un virus-adéno-associé pour l'utilisation thérapie génique
KR20030068337A (ko) * 2002-02-15 2003-08-21 사회복지법인삼성생명공익재단(삼성서울병원) 유전자치료용 진핵발현벡터
KR20030070702A (ko) * 2002-02-26 2003-09-02 사회복지법인삼성생명공익재단(삼성서울병원) 전기적 자극을 이용한 ｄｎａ 전달방법 및 이를 이용한 에리스로포이에틴 발현 방법
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
AU2283895A (en) * 1994-04-11 1995-10-30 Sloan-Kettering Institute For Cancer Research Defective herpes and defective adeno-associated virus vectors with p53 for the treatment of cancer

Also Published As

Publication number Publication date
EP0928202A1 (fr) 1999-07-14
AU743335B2 (en) 2002-01-24
WO1998013070A1 (fr) 1998-04-02
EP0928202A4 (fr) 2001-09-05
KR20000048623A (ko) 2000-07-25
JP2001501819A (ja) 2001-02-13
AU4736797A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
CA2223837C (fr) Transduction de myoblastes par vecteurs de virus adeno-associes
US20020172663A1 (en) Localized myocardial injection method for treating ischemic myocardium
CA2319664A1 (fr) Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf
US20110044947A1 (en) Methods of treating cardiac disorders
EA036051B1 (ru) РЕКОМБИНАНТНЫЙ АДЕНОАССОЦИИРОВАННЫЙ ВЕКТОР (rAAV), СПОСОБНЫЙ ПРОНИКАТЬ СКВОЗЬ ГЕМАТОЭНЦЕФАЛИЧЕСКИЙ БАРЬЕР (ГЭБ), И ЕГО ПРИМЕНЕНИЕ ДЛЯ ВОССТАНОВЛЕНИЯ ЭКСПРЕССИИ Glut1
US6989374B1 (en) Gene therapy for cardiomyopathy
AU763049B2 (en) Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
AU743335B2 (en) Non-invasive administration of adeno-associated viral vectors
KR20010108053A (ko) 당뇨병성 허혈성 질환 유전자 치료
AU737129B2 (en) Long-term expression of gene products by transforming muscle cells
JP2002522558A (ja) エリスロポエチンをコードするアデノウイルスベクター及び遺伝子治療におけるそれらの使用
US7196062B2 (en) Method for treating glaucoma
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
US11891429B2 (en) Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
WO2024094009A1 (fr) Cassette d'expression pour gène cible et son utilisation
AU758530B2 (en) Delivery of multiple genes to cells using plural adeno-associated viral vectors
AU763063B2 (en) AAV transduction of myoblasts
WO2008130949A2 (fr) Modulation de l'expression de nurr1 dans une cellule

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead